Amylyx Pharmaceuticals, Inc. AMLX Enterprise value

Enterprise value at other companies

MBX Biosciences, Inc.MBX

$1.37B+533%

Viking TherapeuticsVKTX

$3.81B-14.5%

Crinetics PharmaceuticalsCRNX

$3.74B+21.5%

VAN

Vivani MedicalVANI

$83.88M+9.2%

uniQureQURE

$2.82B+376%

MeiraGTx Holdings plcMGTX

$696.49M+26.9%

FAQ

What is Amylyx Pharmaceuticals, Inc.'s enterprise value?

Amylyx Pharmaceuticals, Inc. (AMLX) reported enterprise value of $1.95B in Q2 2026.

How has Amylyx Pharmaceuticals, Inc.'s enterprise value changed year-over-year?

Amylyx Pharmaceuticals, Inc.'s enterprise value increased by 276.1% year-over-year, from $519.27M to $1.95B.

What is the long-term trend for Amylyx Pharmaceuticals, Inc.'s enterprise value?

Over 3 years (2022 to 2025), Amylyx Pharmaceuticals, Inc.'s enterprise value has grown at a -22.3% compound annual growth rate (CAGR), from $2.36B to $1.11B.

What does enterprise value mean?

Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.